India, with over 101 million diabetes patients and rising obesity rates, faces a critical need for effective treatment ...

Eli Lilly and Co. has begun selling its blockbuster weight-loss and diabetes drug Mounjaro in India, pipping rivals in a ...

The much-awaited launch of Mounjaro, an injectable drug used to treat obesity, overweight, and type 2 diabetes, has been ...

Eli Lilly and Company (India) on Thursday said it has launched a first-of-its-kind medication for obesity and type 2 diabetes ...

The single-dose vial presentation has marketing authorization from the national drugs regulator—Central Drugs Standard ...

US pharma major Eli Lilly has launched in India its eagerly awaited diabetes and obesity drug Mounjaro tripeptide Read ahead ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

US pharma giant Eli Lilly's Mounjaro can prove crucial in treatment of obesity & type 2 diabetes. Launched in the US in 2022, ...

Once-a-weekly, prescription-based medicine, Mounjaro is a single molecule that selectively binds to and activates both GIP ...